Prevencio has reported study data where its artificial intelligence (AI)-powered HART CVE blood test demonstrated precise prediction of whether patients with diabetes would have a heart attack or major cardiac event within the next year.
The latest data is from a study carried out at Massachusetts General Hospital in the US.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It indicates that the test can substantially enhance the risk classification of patients with diabetes, permitting intensive treatment in increased risk people and averting costly or invasive treatment in patients who are at reduced risk.
Cardiologists from the hospital tested 450 participants, predicting their one-year risk of heart attack, stroke or cardiovascular death.
On categorising the score into low-risk and high-risk groups, the test demonstrated a precise hazard ratio (HR) of 25, showing that high-risk patients with diabetes had a 25-fold increased risk of a major cardiac event within a year versus low-risk patients without diabetes.
Patients with diabetes as well as suspected or known stable and acute heart disease, for which there exist minimal prognostic risk models, could benefit from the multiple protein, weighted risk test.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataPrevencio also provides a second multi-protein blood test, HART CADhs, to detect obstruction in the arteries of the heart.
HART CADhs was demonstrated to be more precise than the standard-of-care stress tests, the company noted.
Both tests are presently offered to medical professionals for patient use.
Prevencio president and CEO Rhonda Rhyne said: “Prevencio is grateful for our collaboration with Massachusetts General Hospital, and we look forward to ongoing improvement in patient care.
“Our mission is to provide clinicians with safer, more accurate and more affordable ways to identify and treat the tens of millions of patients with diabetes and cardiac issues.”
